Suppr超能文献

格雷夫斯病中的细胞间黏附分子-1(ICAM-1):体内与体外结果的对比

Intercellular adhesion molecule-1 (ICAM-1) in Graves' disease: contrast between in vivo and in vitro results.

作者信息

Ciampolillo A, Napolitano G, Mirakian R, Miyasaki A, Giorgino R, Bottazzo G F

机构信息

Department of Immunology, London Hospital Medical College, UK.

出版信息

Clin Exp Immunol. 1993 Dec;94(3):478-85. doi: 10.1111/j.1365-2249.1993.tb08221.x.

Abstract

We have reassessed the possible role of the adhesion molecule ICAM-1 in the pathogenesis of thyroid autoimmunity. In order to do that, we have investigated its expression in eight Graves' thyroids both in vivo (i.e. on cryostat sections and on cell suspensions), and in vitro (i.e. on cells cultured in monolayers for 3 days), and the results were compared with those obtained with similar preparations from four normal glands. On cryostat sections, the expression of ICAM-1, and for comparison that of HLA Class I and Class II molecules, was studied by immunofluorescence (IFL), but the former were also assessed by a distinct immunohistochemical technique. ICAM-1 was not detected in thyrocytes in vivo of both normal and Graves' glands, but solely in endothelial cells and antigen-presenting cells (APC). This selective reaction was confirmed by a four-layer technique using specific markers which identify endothelial cells and thyrocytes. HLA Class II molecules were confirmed to be inappropriately expressed in thyrocytes of Graves' glands, but there was no co-expression of these products and ICAM-1 in the same cells. In contrast, ICAM-1 appeared de novo in a proportion of Graves' and normal thyrocytes soon after the attachment and spreading of these cells in monolayer cultures (36-48 h). Graves' thyrocytes showed a quantitatively higher degree of expression compared with that detected on normal thyroid cells (40-70% versus 12-20%). Under these experimental conditions, the four-layer staining with thyroid microsomal antibodies confirmed that thyrocytes were indeed the positive cells which expressed ICAM-1. Blocking experiments with cultured thyrocytes from two Graves' glands and MoAbs to tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) did not prevent the occurrence of ICAM-1 expression. As a result of our study, we failed to demonstrate that Graves' thyrocytes express ICAM-1 in vivo. The unexpected case of inducing ICAM-1 on thyroid cells under certain in vitro conditions remains intriguing. The phenomenon could be the simple consequence of a mechanical effect rather than exerted by specific biological processes. Further investigations are, therefore, needed to establish whether ICAM-1 is really involved in the pathogenesis of Graves' disease.

摘要

我们重新评估了黏附分子细胞间黏附分子-1(ICAM-1)在甲状腺自身免疫发病机制中的可能作用。为此,我们研究了其在8例格雷夫斯病甲状腺组织中的表达情况,包括体内(即冷冻切片和细胞悬液)和体外(即单层培养3天的细胞),并将结果与4例正常甲状腺组织类似标本的结果进行比较。在冷冻切片上,通过免疫荧光(IFL)研究ICAM-1的表达,以及作为对照的HLA I类和II类分子的表达,但前者也通过一种独特的免疫组织化学技术进行评估。在正常和格雷夫斯病甲状腺组织的体内甲状腺细胞中均未检测到ICAM-1,仅在内皮细胞和抗原呈递细胞(APC)中检测到。使用识别内皮细胞和甲状腺细胞的特异性标记物的四层技术证实了这种选择性反应。HLA II类分子在格雷夫斯病甲状腺细胞中被证实存在异常表达,但这些产物与ICAM-1在同一细胞中没有共表达。相反,在单层培养(36 - 48小时)中,这些细胞附着并铺展后不久,一部分格雷夫斯病和正常甲状腺细胞中出现了ICAM-1的从头表达。与正常甲状腺细胞相比,格雷夫斯病甲状腺细胞的表达量在数量上更高(40 - 70%对12 - 20%)。在这些实验条件下,用甲状腺微粒体抗体进行的四层染色证实甲状腺细胞确实是表达ICAM-1的阳性细胞。用来自两个格雷夫斯病腺体的培养甲状腺细胞以及针对肿瘤坏死因子-α(TNF-α)和干扰素-γ(IFN-γ)的单克隆抗体进行的阻断实验并不能阻止ICAM-1表达的发生。作为我们研究的结果,我们未能证明格雷夫斯病甲状腺细胞在体内表达ICAM-1。在某些体外条件下甲状腺细胞上诱导ICAM-1这一意外情况仍然很有趣。这种现象可能是机械效应的简单结果,而非由特定生物学过程产生。因此,需要进一步研究以确定ICAM-1是否真的参与格雷夫斯病的发病机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4143/1534449/0d2ef43549ca/clinexpimmunol00020-0090-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验